Association of TIMP-1 and TIMP-2 Gene Polymorphisms with Progression of Liver Fibrosis in Patients with Type C Chronic Liver Disease

[1]  Chuanlong Zhu,et al.  Inhibitory Effect of Antisense Oligonucleotide Targeting TIMP-2 on Immune-Induced Liver Fibrosis , 2010, Digestive Diseases and Sciences.

[2]  P. Wang,et al.  Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[3]  P. Marcellin.  Hepatitis B and hepatitis C in 2009 , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[4]  W.C. Chen,et al.  Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[5]  R. Zhou,et al.  Polymorphisms in the matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 and the risk of human adenomyosis , 2008, Environmental and molecular mutagenesis.

[6]  C. Pilarsky,et al.  Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Polymorphisms in a Caucasian Population with Abdominal Aortic Aneurysm , 2007, World Journal of Surgery.

[7]  D. Hommes,et al.  Role of matrix metalloproteinase,tissue inhibitor of metalloproteinase and tumor necrosis factor-α single nucleotide gene polymorphisms in inflammatory bowel disease , 2007 .

[8]  E. Roeb,et al.  Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. , 2007, Journal of hepatology.

[9]  Yukihiro Kishimoto,et al.  Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C , 2007, Hepatology.

[10]  D. Hommes,et al.  Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. , 2007, World journal of gastroenterology.

[11]  P. O-Charoenrat,et al.  The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. , 2006, Oral oncology.

[12]  J. McCubrey,et al.  Analysis of TIMP‐1 Gene Polymorphisms in Italian Sclerodermic Patients , 2006, Journal of clinical laboratory analysis.

[13]  K. Sekizawa,et al.  Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms , 2005, Respirology.

[14]  W. Tan,et al.  Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. , 2003, Carcinogenesis.

[15]  I. König,et al.  Tissue Inhibitor of Metalloproteinases-1, −2, and −3 Polymorphisms in a White Population With Intracranial Aneurysms , 2003, Stroke.

[16]  M. Bernardo,et al.  TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. , 2003, The Biochemical journal.

[17]  K. Brew,et al.  Protein Engineering of the Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Inhibitory Domain , 2003, The Journal of Biological Chemistry.

[18]  J. Hoofnagle,et al.  Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. , 2003, Gastroenterology.

[19]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[20]  T. Asselah,et al.  Fibrosis and disease progression in hepatitis C , 2002, Hepatology.

[21]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[22]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[23]  S. Geller.  Hepatitis B and hepatitis C. , 2002, Clinics in liver disease.

[24]  K. Sekizawa,et al.  Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. , 2001, The European respiratory journal.

[25]  M. Arthur.  Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[26]  Y Ikuta,et al.  Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[27]  M. Polette,et al.  Membrane-type metalloproteinases in tumor invasion. , 1998, The international journal of biochemistry & cell biology.

[28]  H. Kawasaki,et al.  Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. , 1997, Journal of hepatology.

[29]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[30]  W. Crosby,et al.  Cycling probe technology with RNase H attached to an oligonucleotide. , 1996, BioTechniques.

[31]  G. Rousseau,et al.  Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Gene.

[32]  Silke Meyer,et al.  Compilation of vertebrate-encoded transcription factors , 1992, Nucleic Acids Res..

[33]  G. Alvarado-Urbina,et al.  Probe amplifier system based on chimeric cycling oligonucleotides. , 1990, BioTechniques.